August Troendle Sells 458 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 458 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total value of $274,978.62. Following the sale, the chief executive officer owned 603,978 shares in the company, valued at approximately $362,622,351.42. This represents a 0.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Medpace Trading Down 0.6%

Medpace stock opened at $578.50 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock has a fifty day simple moving average of $536.23 and a two-hundred day simple moving average of $492.35. The firm has a market cap of $16.15 billion, a price-to-earnings ratio of 33.91, a PEG ratio of 2.58 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period in the prior year, the company posted $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the topic of several research analyst reports. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Robert W. Baird boosted their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Mizuho boosted their price objective on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, TD Cowen increased their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Medpace during the 2nd quarter valued at $1,323,047,000. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the period. Madison Asset Management LLC purchased a new stake in Medpace in the 2nd quarter worth $128,956,000. Arrowstreet Capital Limited Partnership increased its stake in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares in the last quarter. Finally, American Capital Management Inc. purchased a new stake in Medpace in the 2nd quarter worth $111,329,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.